Daniel E. Owens - Mar 15, 2023 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Role
Chief Human Resources Officer
Signature
Lisa Taylor as Attorney-in-fact for Dan Owens
Stock symbol
TMCI
Transactions as of
Mar 15, 2023
Transactions value $
-$99,031
Form type
4
Date filed
3/17/2023, 09:00 PM
Previous filing
Mar 10, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMCI Common Stock Options Exercise $43.9K +6.25K +20.22% $7.03 37.2K Mar 15, 2023 Direct F1, F2
transaction TMCI Common Stock Sale -$143K -6.25K -16.82% $22.87 30.9K Mar 15, 2023 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TMCI Stock Option Right to Buy Options Exercise $0 -6.25K -3.42% $0.00 176K Mar 15, 2023 Stock Option Right to Buy 6.25K $7.03 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Daniel E. Owens is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 Includes 25,650 RSUs.
F3 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.6600 to $23.3900 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The stock option vests in equal annual installments over 4 years, commencing on February 2, 2022, with the last installment on February 2, 2025, subject to Reporting Person's providing continued service to Issuer through each vesting date.